Alcolase, a Copenhagen-based biotech startup, has raised €1.5 million in seed funding to advance its enzyme-based technology designed to treat alcohol intolerance caused by genetic differences. The funding round was led by Ada Ventures, with participation from Delphinus Venture Capital, Antler, Manigoff Invest, and a group of business angels.
The Danish company, founded in 2020, is developing a therapeutic approach that breaks down alcohol in the stomach before it can be absorbed into the bloodstream. This innovation targets individuals with ALDH2 deficiency, a genetic condition affecting approximately 540 million people globally, predominantly in East Asia. The condition causes uncomfortable physical reactions when these individuals consume alcohol, including flushing, nausea, and heart palpitations.
Addressing a Market Need Beyond Recreation
Alcolase’s approach reframes alcohol intolerance not as a lifestyle preference but as a social inclusion issue. According to Mikkel Precht, CEO and Co-founder, “When you speak to people with alcohol intolerance, you realise this is not about wanting to drink more. It is about not being shut out of dinners, work events and family gatherings because of a genetic difference. We want to give people a real choice they are currently denied.”
The sentiment reflects a significant gap in current treatment options. While ALDH2 deficiency is one of the most common genetic conditions globally, few therapeutic solutions exist for those affected, leaving millions navigating social and professional situations where alcohol consumption carries cultural or business significance.
Funding to Drive Clinical and Commercial Expansion
The newly secured capital will be allocated across multiple strategic priorities. Alcolase plans to conduct in vivo studies to validate its enzyme technology’s efficacy and safety, strengthen its intellectual property portfolio to protect its innovations, and establish commercial partnerships across key markets. The company is simultaneously expanding its UK subsidiary to support therapeutic drug delivery development, positioning itself for regulatory pathways in multiple jurisdictions.
The startup has also identified Singapore and South Korea as initial launch markets, capitalizing on the high prevalence of ALDH2 deficiency in these regions and their advanced healthcare infrastructure.
Growing European Biotech Ambition
Alcolase’s funding round reflects the continued vibrancy of the European biotech sector, particularly in Northern Europe where Denmark has established itself as a hub for life sciences innovation. The involvement of established venture capital firms like Ada Ventures and Antler demonstrates investor confidence in enzyme-based therapeutic approaches and the market opportunity surrounding genetic conditions. As European startups increasingly target global health challenges with novel biological solutions, companies like Alcolase exemplify how regional expertise can address unmet medical needs affecting hundreds of millions of people worldwide.